Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) - Laporan Laba Rugi (TTM)

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)
EG ˙ CASE
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 947 960 1,010 1,060 1,140 1,246 1,321 1,420 1,487 1,484 1,533 1,615 1,779 1,922 1,987 2,101 2,319 2,769 3,178 3,576
Change (%) 1.35 5.22 4.96 7.48 9.36 5.95 7.54 4.71 -0.20 3.30 5.35 10.17 8.05 3.34 5.76 10.35 19.41 14.79 12.54
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 489 514 545 575 622 670 693 743 761 765 809 854 948 1,018 1,064 1,116 1,251 1,487 1,692 1,891
Change (%) 5.24 5.94 5.61 8.02 7.72 3.46 7.22 2.44 0.57 5.67 5.65 10.98 7.40 4.46 4.88 12.15 18.86 13.75 11.78
% of Revenue 51.59 53.57 53.93 54.27 54.54 53.72 52.46 52.30 51.17 51.57 52.75 52.90 53.29 52.97 53.54 53.10 53.96 53.72 53.23 52.87
Gross Operating Profit 459 446 465 485 518 577 628 677 726 719 724 761 831 904 923 985 1,067 1,281 1,486 1,686
Change (%) -2.79 4.39 4.21 6.83 11.32 8.85 7.89 7.19 -1.02 0.77 5.01 9.26 8.80 2.09 6.78 8.31 20.06 15.98 13.40
% of Revenue 48.41 46.43 46.07 45.73 45.46 46.28 47.54 47.70 48.83 48.43 47.25 47.10 46.71 47.03 46.46 46.90 46.04 46.28 46.77 47.13
SG&A 253 260 267 273 283 303 310 334 349 382 397 413 443 466 489 517 533 586 636 709
Change (%) 2.87 2.60 2.53 3.30 7.35 2.35 7.69 4.38 9.61 3.79 4.07 7.21 5.13 5.02 5.69 3.06 9.98 8.59 11.47
% of Revenue 26.68 27.08 26.40 25.79 24.79 24.33 23.51 23.54 23.46 25.77 25.90 25.58 24.90 24.22 24.62 24.60 22.97 21.16 20.02 19.83
R&D
Change (%)
% of Revenue
OpEx 740 773 811 848 903 972 1,002 1,072 1,104 1,142 1,199 1,265 1,388 1,477 1,544 1,624 1,774 2,046 2,300 2,571
Change (%) 4.50 4.83 4.61 6.55 7.61 3.11 6.91 3.04 3.39 5.04 5.51 9.73 6.35 4.58 5.14 9.27 15.30 12.43 11.77
% of Revenue 78.10 80.52 80.22 79.95 79.26 77.99 75.90 75.46 74.26 76.94 78.23 78.35 78.04 76.81 77.73 77.28 76.52 73.89 72.37 71.88
Operating Income 208 187 200 213 236 274 318 348 383 342 334 350 391 446 442 477 544 723 878 1,006
Change (%) -9.88 6.85 6.41 11.17 16.04 16.03 9.50 9.82 -10.57 -2.50 4.78 11.74 14.09 -0.77 7.93 14.02 32.81 21.46 14.55
% of Revenue 21.90 19.48 19.78 20.05 20.74 22.01 24.10 24.54 25.74 23.06 21.77 21.65 21.96 23.19 22.27 22.72 23.48 26.11 27.63 28.12
Interest Expense -102 -97 -94 -92 -92 -91 -89 -87 -87 -89 -98 -122 -156 -191 -222 -253 -261 -307 -377 -434
Change (%) -5.10 -2.29 -2.34 -0.66 -0.64 -2.05 -2.85 0.82 2.00 10.41 24.19 28.03 22.28 15.94 14.16 3.31 17.51 22.70 15.17
% of Revenue -10.75 -10.07 -9.35 -8.70 -8.04 -7.30 -6.75 -6.10 -5.87 -6.00 -6.42 -7.56 -8.79 -9.95 -11.16 -12.04 -11.28 -11.10 -11.86 -12.14
Net Income 119 112 121 130 151 181 222 244 269 246 240 237 243 245 235 248 287 387 413 439
Change (%) -6.08 8.02 7.43 15.68 20.25 22.59 9.69 10.42 -8.64 -2.15 -1.35 2.36 0.87 -3.88 5.39 15.88 34.77 6.51 6.45
% of Revenue 12.61 11.68 11.99 12.28 13.21 14.53 16.81 17.15 18.08 16.56 15.68 14.69 13.64 12.74 11.85 11.80 12.40 13.99 12.98 12.28

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista